Breaking News, Collaborations & Alliances

IDRI, Duke Vax Institute, 3M Partner on Adjuvant COVID Vax

Studies show 3M-052/Alum formulation elicits a strong, durable immune response against several strains of coronavirus, including bat coronaviruses.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The Infectious Disease Research Institute (IDRI), Duke Human Vaccine Institute, and 3M have collaborated to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2, as well as other coronaviruses. Study results show the vaccine candidate, which combines a nanoparticle developed by a Duke-led research team with the IDRI’s novel formulation of 3M’s “3M-052” compound, stimulates increased levels of production of “broadly ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters